New Results
Multiple Low Dose (MLD) therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
View ORCID ProfileJoão M. Fernandes Neto, Ernest Nadal, Salo N Ooft, Evert Bosdriesz, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, Emile Voest, Lodewyk F.A. Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
doi: https://doi.org/10.1101/821975
João M. Fernandes Neto
1Division of Molecular Carcinogenesis & Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Ernest Nadal
2Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L’Hospitalet del Llobregat, Barcelona, Spain
Salo N Ooft
3Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
Evert Bosdriesz
1Division of Molecular Carcinogenesis & Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Lourdes Farre
2Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L’Hospitalet del Llobregat, Barcelona, Spain
4Institute Gonçalo Moniz. Fundaçao Oswaldo Cruz (FIOCRUZ), Brasil
Chelsea McLean
3Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
Sjoerd Klarenbeek
5Experimental Animal Pathology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
Anouk Jurgens
1Division of Molecular Carcinogenesis & Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Hannes Hagen
1Division of Molecular Carcinogenesis & Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Liqin Wang
1Division of Molecular Carcinogenesis & Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Enriqueta Felip
6Department of Medical Oncology, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
7Autonomous University of Barcelona (UAB), Barcelona, Spain
Alex Martinez-Marti
6Department of Medical Oncology, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
7Autonomous University of Barcelona (UAB), Barcelona, Spain
Emile Voest
3Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
Lodewyk F.A. Wessels
1Division of Molecular Carcinogenesis & Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Olaf van Tellingen
8Division of Clinical Pharmacology, The Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
Alberto Villanueva
2Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L’Hospitalet del Llobregat, Barcelona, Spain
9Xenopat S.L., Business Bioincubator, Bellvitge Health Science Campus, Barcelona, Spain
René Bernards
1Division of Molecular Carcinogenesis & Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
Article usage
Posted October 29, 2019.
Multiple Low Dose (MLD) therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
João M. Fernandes Neto, Ernest Nadal, Salo N Ooft, Evert Bosdriesz, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, Emile Voest, Lodewyk F.A. Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
bioRxiv 821975; doi: https://doi.org/10.1101/821975
Multiple Low Dose (MLD) therapy: an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
João M. Fernandes Neto, Ernest Nadal, Salo N Ooft, Evert Bosdriesz, Lourdes Farre, Chelsea McLean, Sjoerd Klarenbeek, Anouk Jurgens, Hannes Hagen, Liqin Wang, Enriqueta Felip, Alex Martinez-Marti, Emile Voest, Lodewyk F.A. Wessels, Olaf van Tellingen, Alberto Villanueva, René Bernards
bioRxiv 821975; doi: https://doi.org/10.1101/821975
Subject Area
Subject Areas
- Biochemistry (11697)
- Bioengineering (8714)
- Bioinformatics (29118)
- Biophysics (14924)
- Cancer Biology (12047)
- Cell Biology (17347)
- Clinical Trials (138)
- Developmental Biology (9405)
- Ecology (14138)
- Epidemiology (2067)
- Evolutionary Biology (18260)
- Genetics (12214)
- Genomics (16759)
- Immunology (11838)
- Microbiology (27986)
- Molecular Biology (11545)
- Neuroscience (60780)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3228)
- Physiology (4937)
- Plant Biology (10381)
- Synthetic Biology (2876)
- Systems Biology (7332)
- Zoology (1642)